BOAN BIOTECH's self-developed drug Dulaglutide Injection has been approved for market launch

華爾街見聞
2025.08.09 13:58
博安生物港交所公告，公司自主開發的博優平®（度拉糖肽注射液）已獲得國家藥品監督管理局的上市批准，用於成人 2 型糖尿病患者的血糖控制。博優平®是一種長效 GLP-1（胰高血糖素樣肽-1）受體激動劑，其在中國大陸的商業化由公司與上藥控股合作開展。
Source: 華爾街見聞 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.